NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Study on the Epidemiology and Testing of Human Epidermal Growth Factor-Receptor 2 (HER2) in Breast Cancer in Germany

NCT02666261

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Breast Cancer

Countries: Germany

This non-interventional study will collect data from routine diagnostics on HER2 testing of breast cancer in Germany.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Samples derived from men and women of age greater than or equal to (\>/=) 18 years
* Samples derived from participants with any stage of histologically confirmed invasive breast cancer with HER2 diagnostics performed within routine (histo-)pathological workup or
* (Histo-)Pathological work-up of the tumor sample as at or after start of this study
* Available information on the year of birth of the participant
* No pre-selection of tumor samples is allowed. Tumor samples have to be documented consecutively in the order of their (histo-)pathological work-up.

Exclusion Criteria:

* Sample derived from participants with any stage of breast cancer with no HER2 diagnostics performed at the time of routine (histo-)pathological work-up.
* Samples derived prior to the start of this study.

Locations (64)

Augsburg, Germany
Bamberg, Germany
Bayreuth, Germany
Bergisch Gladbach, Germany
Berlin, Germany
Berlin, Germany
Berlin, Germany
Berlin - Spandau, Germany
Bocholt, Germany
Bochum, Germany
Bonn, Germany
Coburg, Germany
Cologne, Germany
Cologne, Germany
Dessau, Germany
Dortmund, Germany
Dresden, Germany
Duisburg, Germany
Düren, Germany
Erlangen, Germany
Frankfurt, Germany
Freiburg im Breisgau, Germany
Friedrichshafen, Germany
Göppingen, Germany
Göttingen, Germany
Grevenbroich, Germany
Gummersbach, Germany
Hagen, Germany
Halle, Germany
Hamburg, Germany
+ 34 more on CT.gov